You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華海藥業(600521.SH):普瑞巴林膠囊獲得藥品註冊證書
格隆匯 10-14 16:32

格隆匯10月14日丨華海藥業(600521.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的普瑞巴林膠囊的《藥品註冊證書》。

普瑞巴林膠囊主要用於治療帶狀皰疹後神經痛、纖維肌痛。普瑞巴林膠囊最早由輝瑞研發,於2004年在英國被批准上市。全球主要生產廠商有UPJOHN US2 LLC、ACTAVIS ELIZABETH LLC、ALEMBIC PHARMACEUTICALS LTD等,國內生產廠商主要有齊魯製藥(海南)有限公司、石藥集團歐意藥業有限公司、華潤雙鶴藥業股份有限公司等。

據統計,2020年4月—2021年3月普瑞巴林製劑產品全球市場銷售額約26.45億美元(數據來源於Newport數據庫);2020年普瑞巴林膠囊國內市場銷售額約人民幣4.335億元(數據來源於米內網)。

截止目前,公司在普瑞巴林膠囊研發項目上已投入研發費用約人民幣1032.66萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account